Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Follow-up of phase I/II study of CaspaCide T cells from an HLA-partially matched family donor after negative selection of TCR αβ+ T cells in pediatric patients affected by hematological disorders

Next Previous
X
Search
Trial Profile

Follow-up of phase I/II study of CaspaCide T cells from an HLA-partially matched family donor after negative selection of TCR αβ+ T cells in pediatric patients affected by hematological disorders

Status: Discontinued
Phase of Trial: Phase I/II

Latest Information Update: 11 Mar 2024

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Rivogenlecleucel (Primary)
  • Indications Haemoglobinopathies; Immunodeficiency disorders; Leukaemia; Myelodysplastic syndromes
  • Focus Therapeutic Use
  • Acronyms CaspaCide TCR alpha beta haplo HSCT
  • Sponsors Bellicum Pharmaceuticals

    • Most Recent Events

    • 08 Mar 2024 Status changed from recruiting to discontinued.
    • 01 Feb 2018 Status changed to recruiting.
    • 10 Jan 2018 New trial record

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top